Company intelligence / Profile preview
Spexis AG
Allschwil, Switzerlandspexisbio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Spexis has multiple clinical candidates in development. ColiFin is approved in Europe for cystic fibrosis and entering global Phase 3 studies. Balixafortide had a negative Phase 3 readout in metastatic breast cancer but is being evaluated for other indications. Lonodelestat and Murepavadin are in earlier clinical development.
- Therapeutic areas
- OncologyPulmonologyRare Diseases
- Modalities
- Macrocyclic moleculesInhaled therapeutics
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Fosun Pharma (China rights to Balixafortide)Santhera (Lonodelestat out-licensed)CF FoundationCARBXIMI
Beyond the preview
Go deeper on Spexis AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spexis AG.